Patterns in use and costs of subsidising 5-aminosalicyclic acid compounds and biologic agents in the treatment of inflammatory bowel disease in Australia.

MLA

Staatz, Christine E., et al. “Patterns in Use and Costs of Subsidising 5-Aminosalicyclic Acid Compounds and Biologic Agents in the Treatment of Inflammatory Bowel Disease in Australia.” Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, vol. 50, no. 3, Mar. 2018, pp. 314–17. EBSCOhost, https://doi.org/10.1016/j.dld.2017.12.016.

APA

Staatz, C. E., Martin, N. S., Kong, D. P., & Hollingworth, S. A. (2018). Patterns in use and costs of subsidising 5-aminosalicyclic acid compounds and biologic agents in the treatment of inflammatory bowel disease in Australia. Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 50(3), 314–317. https://doi.org/10.1016/j.dld.2017.12.016

Chicago

Staatz, Christine E, Neal S Martin, David P Kong, and Samantha A Hollingworth. 2018. “Patterns in Use and Costs of Subsidising 5-Aminosalicyclic Acid Compounds and Biologic Agents in the Treatment of Inflammatory Bowel Disease in Australia.” Digestive and Liver Disease : Official Journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 50 (3): 314–17. doi:10.1016/j.dld.2017.12.016.